Reliability of core needle biopsy for determining ER and HER2 status in breast cancer

By Dekker T. J. A.   Smit V. T. H. B. M.   Hooijer G. K. J.   Van de Vijver M. J.   Mesker W. E.   Tollenaar R. A. E. M.   Nortier J. W. R.   Kroep J. R.  

Annals of Oncology, Vol. 24, Iss. 4, 2013-04 ,pp. : 931-937

Oxford University Press

Access to resources Recommend Favorite

Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer

By Sari Ebru  

Medical Oncology, Vol. 28, Iss. 1, 2011-03 ,pp. : 57-63

Humana Press, Inc

Access to resources Recommend Favorite

Promoter methylation status of the FHIT gene and Fhit expression: Association with HER2/neu status in breast cancer patients

By            

Oncology Reports, Vol. 30, Iss. 5, 2013-01 ,pp. : 2270-2278

Spandidos Publications

Access to resources Recommend Favorite

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer

By Lipton Allan   Goodman Laurie   Leitzel Kim   Cook Jennifer   Sperinde Jeff   Haddad Mojgan   Köstler Wolfgang   Huang Weidong   Weidler Jodi   Ali Suhail   Newton Alicia   Fuchs Eva-Marie   Paquet Agnes   Singer Christian   Horvat Reinhard   Jin Xueguang   Banerjee Joyee   Mukherjee Ali   Tan Yuping   Shi Yining   Chenna Ahmed   Larson Jeff   Lie Yolanda   Sherwood Thomas   Petropoulos Christos   Williams Stephen   Winslow John   Parry Gordon   Bates Michael  

Breast Cancer Research and Treatment, Vol. 141, Iss. 1, 2013-08 ,pp. : 43-53

Springer Publishing Company

Access to resources Recommend Favorite

HER2 status in a population-derived breast cancer cohort: discordances during tumor progression

By Wilking Ulla  

Breast Cancer Research and Treatment, Vol. 125, Iss. 2, 2011-01 ,pp. : 553-561

Springer Publishing Company

Access to resources Recommend Favorite